STAT3 and lung disorder: Currently, direct STAT3 targeting primarily focuses on inhibiting functional dimerization by blocking its SH2 domain—the pivotal mediator of STAT3 dimerization and one of the most rapidly advancing therapeutic targets in pulmonary diseases (21).